Qingdao Baheal Medical Inc.
301015.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.63B
Close$
$48.78
115.8% upside
Current Fair Value
115.8% upsideUndervalued by 115.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.63 Billion |
|---|---|
| Enterprise Value | $15.69 Billion |
| Dividend Yield | $0.57 (2.20%) |
| Earnings per Share | $0.9 |
| Beta | 0.42 |
| Outstanding Shares | 525,624,077 |
Return
| Return on Equity | 22.39% |
|---|---|
| Return on Assets | 6.72% |
| Return on Invested Capital | 22.20% |
Valuation & Multiples
| P/E Ratio | 27.11 |
|---|---|
| PEG | 93.72 |
| Price to Sales | 1.74 |
| Price to Book Ratio | 4.52 |
| Enterprise Value to Revenue | 2.14 |
| Enterprise Value to EBIT | 16.93 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 1.6 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.76 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Qingdao Baheal Medical Inc.
2,493 employees
CEO: Gang Fu Qingdao Baheal Medical Inc., established in 2005 and headquartered in Qingdao, China, operates as a pharmaceutical company. The firm's activities encompass the entire spectrum of drug development, from initial research to manufacturing a...